1256387-73-1Relevant articles and documents
Preparation method of ledipasvir key intermediate
-
Paragraph 0017, (2017/01/31)
The invention relates to a preparation method of a ledipasvir key intermediate, and concretely relates to a preparation method of t-butyl (1R,3S,4S)-3-(5-halo-1H-benzimidazolyl-2-yl)-2-azabicyclo[2. 2. 1]heptane-carboxylate. The method has the advantages of low price and massive commercial purchasing of a raw material, and complete avoiding of generation of disubstituted impurities.
Hepatitis C virus inhibitor, medical composition and application thereof
-
Paragraph 0069; 0070, (2017/04/18)
The invention provides a hepatitis C virus inhibitor, a medical composition and application thereof. The hepatitis C virus inhibitor is a compound as shown in a formula (I), or salt, hydrate or a solvent compound accepted in crystal forms and pharmacy. The compound disclosed by the invention has better hepatitis C viral protein NS5A restraining activity, has better pharmacodynamics/pharmacokinetics properties, is good in applicability and high in safety, can be used for preparing medicines for treating hepatitis C virus infection, and has favorable market development prospects.
SOLID FORMS OF AN ANTIVIRAL COMPOUND
-
Paragraph 0252-0253, (2014/01/07)
Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.